REFRACTORY HEPATOBLASTOMA
Clinical trials for REFRACTORY HEPATOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEPATOBLASTOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEPATOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: Two-Drug attack on tumors
Disease control Recruiting nowThis study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …
Matched conditions: REFRACTORY HEPATOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for young cancer patients: experimental drug targets recurrent tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …
Matched conditions: REFRACTORY HEPATOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New registry aims to crack the code on tough childhood liver cancer
Knowledge-focused Recruiting nowThis study is creating a registry for children and adults whose liver cancer (hepatoblastoma) has come back or not responded to treatment. Researchers will collect medical information, tumor samples, and scans from up to 500 participants to learn more about the disease. The goal …
Matched conditions: REFRACTORY HEPATOBLASTOMA
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC